

Implementing quality management systems in national regulatory authorities:

Examples and practices



World Health
Organization

Implementing quality management systems in national regulatory authorities:

Examples and practices



**World Health
Organization**

Implementing quality management systems in national regulatory authorities: examples and practices

ISBN 978-92-4-002237-9 (electronic version)

ISBN 978-92-4-002238-6 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Implementing quality management systems in national regulatory authorities: examples and practices. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	iv
Abbreviations & Glossary	v
1. Background	1
2. Objective	1
3. Scope	2
4. Use of Examples	2
4.1. Presentation of the examples in this document	3
5. QMS requirements for NRAs	4
5.1. Scope of the QMS	4
5.2. Organizational context of the NRA	4
5.3. Leadership, management and organization	20
5.4. Document and data management	24
5.5. Planning	25
5.6. Support and resources	32
5.7. Operation	36
5.8. Performance evaluation	40
5.9. Improvement	50
References	54
Further reading	54

Acknowledgements

Mr Y. Al-Nujaym, Saudi Food and Drug Authority, Saudi Arabia; Ms H. Baiao, Portuguese Authority for Medicines and Health Products (INFARMED); Dr O.A.M.A. Badary, National Organization for Drug Control and Research, Egypt; Ms R. Bose, Central Drugs Standard Control Organisation, India (CDSCO); Ms G.F. Ferreiro, Centro para el Control Estatal de Medicamento, Equipos y Dispositivos Médicos, Cuba; Ms A. Julsing and Mr K. Bokaba, Medicines Control Council, South Africa; Ms B. Holst, Danish Medicines Agency (DKMA); Ms Y. Lee, Ministry of Food and Drug Safety, Republic of Korea; Dr R. Lino de Brito and Dr P. Serpa, Agência Nacional de Vigilância Sanitária, Brazil; Ms G. Mahlangu, Medicines Control Authority of Zimbabwe (MCAZ); Ms L. Margaryants, Scientific Centre of Drug and Medical Technology Expertise, Armenia; Ms G. Mkomagi, Tanzania Food and Drug Authority, United Republic of Tanzania; Ms M. Muñozcano Quintanar, Comisión Federal para la Protección contra Riesgos Sanitarios, Mexico; Mr G. Muthuri Francis, Pharmacy and Poisons Board, Kenya; Ms A. Olivares, Comisión Federal para la Protección contra Riesgos Sanitarios, Mexico; Mr P. Osatapirat, Thailand Food and Drug Administration, Thailand; Ms H. Qorani, Jordan Food and Drug Administration, Jordan; and Dr C. P. Alfonso, Mr S. Arora, Mr. M. Conrad, Dr N. Dellepiane, Dr R.O.A. Dehaghi, Mr. M. F. Dias, Dr. E. Elhosary, Dr. V. Gigante, Dr. A. B. Khadem, Mr. J. R. H. Kuwana, Dr. B. Meade, Mr. M. M. J. Musonda, Mr. S. Onen, Ms. D. Pirgari, Ms S. Ramirez, Mr. M. Refaat, Dr M. E. C. Roldao Santos, Mr. H. Sillo, Mr. M. Ward, World Health Organization, Switzerland.

Abbreviations & Glossary

The glossary is the same as that of the WHO Guideline on implementation of QMS for NRAs, Annex 13, WHO Technical Report Series, No. 1025.

Abbreviations

ADR	Adverse drug report
CAPA	Corrective and Preventive Action
CT	Clinical Trial Oversight (GBT regulatory function)
EMA	European Medicines Agency
EU	European Union
GBT	Global Benchmarking Tool
GxP	Good Practices (Manufacturing-M, Clinical-C, Distribution-D, Laboratory-L, Regulatory-R, Review-Rev)
HMA	The Heads of Medicines Agencies
IT	Information Technology
ISO	International Standardization Organization
KPI	Key Performance Indicator
LI	Licensing Establishments (GBT regulatory function)
LR	Lot Release (GBT regulatory function)
LT	Laboratory Access and Testing (GBT regulatory function)
LIMS	Laboratory information management system
LSP	Lot summary protocol
MA	Marketing Authorization (GBT regulatory function)
MAH	Marketing Authorization Holder
MC	Market Surveillance and Control (GBT regulatory function)
MOH	Ministry of Health
NRA	National Regulatory Authority
PDCA	Plan, Do, Check and Act
PV	Pharmacovigilance (equivalent to Vigilance regulatory function)
QA	Quality Assurance
QMS	Quality Management System
RCA	Root cause analysis
RI	Regulatory Inspection (GBT regulatory function)
RS	Regulatory System (GBT regulatory function)
SF	Substandard or falsified
SOP	Standard Operating Procedure
TM	Top management
VL	Vigilance (GBT regulatory function)
WHA	World Health Assembly
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23772

